Press Releases

Alexander Hardy, CEO of Genentech, Joins Syapse Board of Directors

San Francisco, Calif. (May 29, 2019) — Syapse, a company powering precision medicine through its global provider network, today announced that Alexander Hardy, CEO of Genentech, a member of the Roche Group, has joined the company’s Board of Directors.

Hardy started at Genentech in 2005, where he held several senior management positions, including leading patient access services and overseeing commercial operations for a range of therapeutic areas including HER2-positive cancer. In 2014, he became head of Asia Pacific for Roche Pharmaceuticals. Prior to his return to Genentech, he was head of Global Product Strategy at Roche.

“Syapse has brought together leading health systems into a unified learning health network to help realize the vision of precision medicine, and build one of the world’s largest networks of oncology real-world evidence,” said Hardy. “This unique network enables health systems and life science companies, who share a common mission of improving patient care and outcomes, to scale the practice of precision medicine. I look forward to collaborating with the Syapse team as they work to build robust, meaningful collaborations focused on solving substantial challenges in oncology.”

“I am honored to welcome Alexander to the Syapse team. His significant expertise in delivering breakthrough oncology therapeutics to market and scaling commercial operations will be a strategic resource for the Syapse team as we expand our partnerships with life sciences companies seeking to utilize real world evidence to accelerate the delivery of new therapies,” said Ken Tarkoff, CEO of Syapse. “We are proud of the collaborations we’ve built across the precision medicine ecosystem and look forward to working closely with Alexander as we grow our business both here in the United States and in East Asia.” 

The Syapse Board of Directors includes: John Kuelper, Director, Ascension Ventures; Gary J. Kurtzman, MD, Managing Director, Safeguard Scientific; Frank Williams, CEO, Evolent Health; Jay Zaveri, Partner, Social Capital, and; Ken Tarkoff, CEO and Jonathan Hirsch, Founder and President, Syapse.

About Syapse

Syapse is on a mission to deliver the best care for every cancer patient through precision medicine. Our insights platform, data sharing network, and industry partnerships enable healthcare providers to bring precision cancer care to every patient who needs it. By bringing together leading healthcare innovators into a unified ecosystem, we have built one of the world’s largest learning health networks of provider-driven precision medicine data. In collaboration with our partners — including Advocate Aurora Health Care, CommonSpirit Health, Henry Ford Health System, Hoag, Swedish Cancer Institute, and Seoul National University Hospital — we are working toward a future in which all cancer patients have access to the best personalized care, regardless of location or income.